Rates of guideline-recommended bone scans were low, and rates of use of bone drugs even lower, among older men on androgen deprivation therapy (ADT) for prostate cancer.
A novel screening tool was able to accurately identify people with high vs low lifetime risks of developing metastatic prostate cancer or dying from the disease across diverse groups of men.